A drug that inhibits the activity of which enzyme would likely relieve depression?

A drug that inhibits the activity of which enzyme would likely relieve depression?

• A. Aldehyde dehydrogenase
• B. Monoamine oxidase A
• C. L-Aromatic amino acid carboxylase
• D. Tryptophan-5-hydroxylase

Answer: (B)

The correct answer is the enzyme monoamine oxidase A (MAO-A). This enzyme is responsible for the breakdown of monoamines, which include key neurotransmitters such as serotonin, norepinephrine, and dopamine. These neurotransmitters play significant roles in mood regulation and are often found to be imbalanced in individuals suffering from depression. Inhibiting MAO-A would prevent the degradation of these neurotransmitters, leading to an increase in their availability in the synaptic cleft. Increased levels of serotonin and norepinephrine can help alleviate symptoms of depression, as these neurotransmitters are critical for mood enhancement and emotional stability. This approach is part of a class of antidepressants known as monoamine oxidase inhibitors (MAOIs), which have been effectively used in the treatment of depression, especially in cases where other treatments may have failed. The relationship between these enzymes and neurotransmitter levels highlights the biochemical pathways involved in mood regulation and the potential for pharmacological intervention to restore balance in individuals experiencing depressive episodes.

The correct answer is the enzyme monoamine oxidase A (MAO-A). This enzyme is responsible for the breakdown of monoamines, which include key neurotransmitters such as serotonin, norepinephrine, and dopamine. These neurotransmitters play significant roles in mood regulation and are often found to be imbalanced in individuals suffering from depression.

Inhibiting MAO-A would prevent the degradation of these neurotransmitters, leading to an increase in their availability in the synaptic cleft. Increased levels of serotonin and norepinephrine can help alleviate symptoms of depression, as these neurotransmitters are critical for mood enhancement and emotional stability.

This approach is part of a class of antidepressants known as monoamine oxidase inhibitors (MAOIs), which have been effectively used in the treatment of depression, especially in cases where other treatments may have failed. The relationship between these enzymes and neurotransmitter levels highlights the biochemical pathways involved in mood regulation and the potential for pharmacological intervention to restore balance in individuals experiencing depressive episodes.